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Efficient Suppression of Hepatitis C 
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Direct-acting antivirals (DAAs) against Hepatitis C virus (HCV) show effective antiviral activity with 
few side effects. However, the selection of DAA-resistance mutants is a growing problem that needs 
to be resolved. In contrast, miR-122 antagonism shows extensive antiviral effects among all HCV 
genotypes and a high barrier to drug resistance. In the present study, we evaluated three DAAs 
(simeprevir, daclatasvir, and sofosbuvir) in combination with anti-miR-122 treatment against HCV 
genotype 1a in cell cultures. We found that combination treatments with anti-miR-122 and a DAA had 
additive or synergistic antiviral effects. The EC50 values of simeprevir in simeprevir-resistant mutants 
were significantly decreased by combining simeprevir with anti-miR-122. A similar reduction in EC50 in 
daclatasvir-resistant mutants was achieved by combining daclatasvir with anti-miR-122. Combination 
treatment in HCV-replicating cells with DAA and anti-miR-122 sharply reduced HCV RNA amounts. 
Conversely, DAA single treatment with simeprevir or daclatasvir reduced HCV RNA levels initially, 
but the levels later rebounded. DAA-resistant mutants were less frequently observed in combination 
treatments than in DAA single treatments. In summary, the addition of miR-122 antagonism to DAA 
single treatments had additive or synergistic antiviral effects and helped to efficiently suppress HCV 
replication and the emergence of DAA-resistant mutants.
About 170 million people worldwide are currently infected with hepatitis C virus (HCV)1 and approximately 
500,000 people die each year from HCV-related liver diseases, such as liver failure and hepatocellular carcinoma2. 
The previous standard of care for HCV was based on PEGylated interferon and ribavirin therapy, which elimi-
nated HCV in about 50% of patients infected with genotype 1 HCV.
The establishment of HCV cell culture systems has facilitated the development of direct-acting antiviral 
reagents (DAAs) targeting the NS3/4A protease, NS5A protein, and NS5B polymerase. The combination of 
a DAA such as NS3/4A protease inhibitor, NS5A inhibitor, or nucleotide analog NS5B polymerase inhibitor, 
with PEGylated interferon and ribavirin has improved sustained virologic response rates compared with the 
standard of care. However, even a DAA combined with PEGylated interferon and ribavirin, it remains difficult 
to treat patients with a poor response to interferon (i.e., null responders and non-CC IL28B)3–5. In addition, 
interferon-based therapies have a number of severe adverse effects. Recently, many combination regimens involv-
ing DAAs without the use of PEGylated interferon, called interferon-free DAA therapies, have been reported 
to dramatically increase the rate of sustained virologic responses. Interferon-free DAA therapies are generally 
accompanied by fewer adverse effects and have a shorter treatment period than interferon-based therapies6,7. 
However, the pre-existence and selection of resistance-associated variants (RAVs) can result in treatment failure8. 
Furthermore, RAVs may remain in the liver for long periods after treatment once selected by DAA therapies; 
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NS5A inhibitor RAVs are particular examples9. RAVs can also interfere with subsequent interferon-free DAA 
therapies because there are a limited number of DAA classes and RAVs sometimes show cross-drug resistance to 
the same class. Therefore, a new strategy to both prevent the emergence of DAA-resistant mutants and effectively 
eliminate pre-existing RAVs is urgently needed.
In addition, apart from the nucleotide analog NS5B polymerase inhibitor sofosbuvir10,11, most DAAs show dif-
ferent antiviral activities against different HCV genotypes. Therefore, new classes of antiviral therapies applicable 
to all HCV genotypes, known as pan-genotypic antiviral therapies, are also needed.
One liver-specific microRNA (miRNA), miR-122, which is abundant in the liver, binds two sites within 
the 5′ untranslated region (UTR) of the viral genome, and recruits the argonaute 2 protein12–14. Through this 
direct interaction with the HCV genome, miR-122 increases HCV genome stability, translation, and amplifi-
cation, which results in increased HCV replication, as discussed in a recent review article15. Hence, sequestra-
tion of miR-122 by anti-miR-122 oligonucleotides could be a valid treatment strategy, as has been proven not 
only in HCV cell culture systems, but also in HCV-infected chimpanzees and humans16,17. Anti-miR-122 ther-
apy using anti-miR-122 oligonucleotides has a number of advantages over interferon-free DAA therapies. First, 
anti-miR-122 therapy is expected to show universal antiviral effects on all HCV genotypes because miR-122 
binding sites at the 5′ UTR are highly conserved among all HCV genotypes18. Second, it provides a high barrier 
to the emergence of resistance because miR-122–binding negative HCV mutants are highly unfit in HCV cell 
culture systems19. Miravirsen (SPC3649) is a 15-base oligonucleotide with locked nucleic acid (LNA) modifi-
cation complementary to part of miR-122. It is one of the most developed anti-miR-122 therapies and has been 
intravenously administered to African green monkeys20. Miravirsen is taken up by hepatocytes and forms stable 
heteroduplexes with miR-122, resulting in efficient depletion of free miR-122. When miravirsen was adminis-
tered to HCV-infected chimpanzees, it effectively suppressed HCV RNA levels without any evidence of resistant 
mutants17. In a phase 2a clinical study, miravirsen administered to HCV-infected patients exerted substantial 
and prolonged dose-dependent reductions in HCV RNA levels without any escape mutants16. However, it might 
be difficult to completely eliminate HCV from infected cells via anti-miR-122 therapy alone because HCV can 
replicate within Hela cells, which do not express miR-12221.
In summary, DAAs can effectively suppress HCV replication and have a low barrier to the emergence of 
DAA-resistant viruses. Conversely, anti-miR-122 therapy has a moderate antiviral activity with a high barrier to 
drug resistance. In this study, we explored whether these two antiviral therapies could compensate for each other’s 
weaknesses and effectively suppress HCV replication in HCV cell culture systems.
Results
Antiviral Effects of DAAs and LNA–anti-miR-122. Although LNA–anti-miR-122 has been added to the 
cell culture medium in previous studies22, we transfected it into cells because transfection is a more effective way 
to suppress HCV replication14. To evaluate the transfection efficiency of single-stranded RNA oligonucleotides, 
we transfected 10 nM FAM-labeled 2′ -O-methyl (2′ OMe) single-stranded RNA, anti-miR-122 2′ OMe12 into Huh-
7.5 cells using siPORT NeoFX Transfection Agent and fluorescence was detected by fluorescence microscopy. 
As shown in Supplementary Fig. S1, almost all cells showed fluorescence from FAM-labeled anti-miR-122 2′ 
OMe transfected cells. To exclude the potential of LNA-anti-miR-122 cytotoxicity, we evaluated the CC50 val-
ues of LNA-anti-miR-122 for naïve FT3-7 cells, Huh-7.5 cells, and Huh-7.5 cells harboring a full-genome HCV 
replicon. The CC50 of LNA-anti-miR-122 was more than 100 nM in the cells tested (Supplementary Fig. S2a–c). 
First, we determined the EC50 values of LNA–anti-miR-122, simeprevir, an inhibitor of NS3/4A, daclatasvir, an 
inhibitor of NS5A, and sofosbuvir, an inhibitor of the nucleotide analog for genotype 1a H77S.3/GLuc2A23 in 
Huh-7.5 cells to be about 10 nM, 2 nM, 10 pM, and 50 nM, respectively. Transfection of single-stranded RNA may 
have potential antiviral effect. To exclude this possibility, we tested the effects of a non-relevant single-stranded 
RNA oligonucleotide as the LNA-RNA-Control on HCV replication. We did not observe any significant effects 
in LNA-RNA-Control on HCV replication (Supplementary Fig. S3). We next examined whether the combination 
of a DAA and LNA–anti-miR-122 could suppress HCV replication more efficiently than a single DAA. In this 
experiment, H77S.3/GLuc2A-replicating cells were treated with a DAA (simeprevir, daclatasvir, or sofosbuvir) 
and/or LNA–anti-miR-122 at their EC50 values. When HCV-replicating cells were treated with both DAA and 
LNA–anti-miR-122, the combination suppressed HCV replication approximately two-fold more efficiently than 
did either agent alone (Fig. 1). The degree of the additional antiviral effects of LNA–anti-miR-122 was compara-
ble among the DAAs tested. These results strongly suggested that there could be additive or synergistic antiviral 
effects in combination therapy with a DAA and LNA–anti-miR-122.
In Vitro Antiviral Activity in Drug-resistant HCV Mutants. Our results indicated that combination 
treatment with LNA–anti-miR-122 and a DAA had a potential synergistic or additive antiviral effect on wild-type 
H77S (Fig. 1). To confirm these potential effects, we examined combinations of LNA–anti-miR-122 with simeprevir, 
daclatasvir, or sofosbuvir. Briefly, we treated H77S.3/GLuc2A-replicating cells with various concentrations of LNA–
anti-miR-122 and DAAs, and the antiviral activity was evaluated via GLuc activity. We then calculated the com-
bination index by using the method of Chou and Talalay with CalcuSyn Software (Supplementary Table S1a–c)24. 
If the combination index was less than 0.8, the two treatments were assumed to have a synergistic effect, while 
if it was between 0.8 and 1.2 their effects were considered additive. A combination of simeprevir and LNA–
anti-miR-122 showed a mostly synergistic antiviral effect (Supplementary Fig. S4a) and we obtained sim-
ilar results with daclatasvir (Supplementary Fig. S4b) and sofosbuvir (Supplementary Fig. S4c). When we 
calculated the EC50 of simeprevir, daclatasvir, and sofosbuvir for wild-type virus in the presence of LNA–anti-
miR-122, it was generally lower for all the DAAs tested, depending on the concentration of LNA–anti-miR-122 
(Supplementary Fig. S4d–f). These data suggest that LNA–anti-miR-122 and DAAs combination treatments show 
synergistic or additive antiviral effect on HCV genotype 1a H77S. At that point, we did not know whether a 
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similar antiviral effect would be observed in DAA-resistant mutants. Thus, we evaluated the antiviral activity of 
combination treatment against well-known DAA-resistant mutants, as summarized in a recent review8. We then 
tested the activity of the combination treatments for the mutants listed in Table 1 and Supplementary Table S2 
(NS3 mutants) and those in Table 2 (NS5A mutants) in the H77S.3/GLuc2A backbone. For this purpose, we 
Figure 1. The potential additive or synergistic antiviral effects of LNA–anti-miR-122 and DAA treatment. 
H77S.3/GLuc2A RNA was transfected into FT3-7 cells and then treated with DMSO, LNA–anti-miR-122, or 
LNA–anti-miR-122 plus DAA. The concentrations of the antiviral drugs (simeprevir, daclatasvir, sofosbuvir, and 
LNA–anti-miR-122) were set to their EC50 values. GLuc activity secreted by H77S.3/GLuc2A RNA-transfected 
cells was determined and normalized to that of the control group. Results are shown as the means + SEM.
Mutants
Concentrations of LNA-anti-miR-122
0 nM 0.5 nM 1 nM 5 nM 8 nM 10 nM 20 nM 30 nM
WT 2.4 1.1 1.2 1.5 ND 1.6 2.0 1.8
Q80R 39.7 24.3 23.7 ND ND 13.1 12.4 11.0
Q80K 34.2 23.0 26.3 19.2 16.7 18.8 23.8 17.9
R155K 189.1 149.7 94.4 93.8 190.4 140.3 139.1 173.1
R155T 64.9 14.2 30.3 29.9 16.9 ND ND ND
A156G 69.9 32.1 34.6 14.1 35.3 39.5 42.4 44.1
D168A 2688.6 1389.2 1058.6 1225.6 1463.3 973.5 ND ND
D168H 2033.9 1378.0 1094.8 966.3 810.7 1045.6 ND ND
D168T 1376.7 418.7 409.5 607.0 573.6 883.7 ND ND
D168V 5566.7 3101.7 2808.2 ND ND 1630.0 3623.1 5010.9
D168Y 923.0 884.5 884.3 429.7 248.7 880.3 ND ND
Q80R + I170T 117.7 66.7 156.4 119.3 73.7 95.2 ND ND
Q80R + D168E 1838.3 820.9 514.2 421.5 207.5 933.3 ND ND
D168E + N174K 808.9 382.9 342.8 318.7 299.2 310.4 ND ND
Table 1.  EC50 Values (nM) of Simeprevir for NS3 Mutants in the Presence of Different Concentrations of 
LNA–anti-miR-122 (Also See Supplementary Table S1). ND: not determined.
Mutants
Concentrations of LNA-anti-miR-122
0 nM 0.5 nM 1 nM 5 nM 8 nM 10 nM
WT 18.8 13.2 17.0 15.4 ND 15.3
Q30R 4370.1 1133.4 975.1 696.4 1593.8 2230.9
L31V 9487.5 8250.2 3853.5 786.7 2332.2 5694.9
Table 2.  EC50 Values (pM) of Daclatasvir for NS5A Mutants in the Presence of Different Concentrations of 
LNA–anti-miR-122. ND: not determined.
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determined that the EC50 values of the DAAs for each mutant at each concentration of LNA–anti-miR-122. LNA–
anti-miR-122 generally ameliorated drug resistance to simeprevir-resistant mutants (Table 1 and Supplementary 
Table S2). For example, in the presence of 0.5 nM LNA–anti-miR-122, the antiviral effects of simeprevir against 
resistance variants were greatly enhanced, and simeprevir susceptibility ranged from no change (V36G, F43S) to 
a 4.6-fold change (R155T). In comparison with cells not treated with LNA–anti-miR-122, changes were approx-
imately 2-fold for most of the other mutants. Interestingly, we did not consistently observe a similar change in 
susceptibility among all combinations of the concentrations tested. For example, the EC50 values of simeprevir 
for the S122R and D168E mutants in the presence of 10 nM LNA–anti-miR-122 were comparable to those in 
the absence of LNA–anti-miR-122. We performed the same study in daclatasvir-resistant variants and observed 
a similar phenomenon (Table 2). In the presence of 1 nM LNA–anti-miR-122, the susceptibility of Q30R and 
L31V mutants to daclatasvir increased about 4.5-fold and 2.5-fold, respectively. The change in susceptibility was 
observed for any combination of concentrations, which differed from the results for the simeprevir-resistant 
mutants. We did not analyze another well-known daclatasvir-resistant mutant, Y93H in NS5A, because the fitness 
of this mutant was too severely impaired to evaluate the change in susceptibility25. We also omitted a well-known 
sofosbuvir-resistant mutant, S282T in NS5B, from our study due to its low capacity for replication11. In summary, 
the potency of DAAs against their corresponding DAA-resistant variants was significantly enhanced in the pres-
ence of LNA–anti-miR-122.
In Vitro Selection of DAA-resistant Mutants with DAAs, LNA–anti-miR-122, or DAA plus LNA–
anti-miR-122 in Genotype 1a H77S-replicating Cells. We anticipated that the synergistic or additive 
antiviral effects of LNA–anti-miR-122 combined with a DAA on HCV replication could prevent the emergence 
of DAA-resistant mutants, which are expected during and/or after treatment with a single DAA. In an in-vitro 
experiment for the efficient selection of drug-resistant mutants, we used a full-genomic bicistronic H77S repli-
con, tat/2A-Neo-H77S, which contains tat, FMDV2A, and a neomycin-resistant gene as a first cistron driven by 
HCV IRES, and HCV polyproteins as a second cistron driven by EMCV IRES. In Huh-7.5 cells maintained for 
a few weeks after transfection of H77S.3/GLuc2A RNA, we found that the numbers of the cells harboring HCV 
decreased over time (data not shown). Moreover, an advantage of using tat/2A-Neo-H77S under G418 selection 
is that cells harboring HCV replication can be continuously selected. HCV polyproteins from the core to NS5B 
driven by EMCV IRES, tat/2A-Neo-H77S RNA, were transfected into Huh-7.5 cells, and transfected cells were 
selected using 1 mg/mL G418 for 2 weeks. We confirmed that all the G418-resistant cells supported HCV replica-
tion via immunofluorescence analysis using anti-core antibody (Supplementary Fig. S5a). Cells were maintained 
in the presence of 1 mg/mL G418 and split twice a week, and 10 nM LNA–anti-miR-122 was transfected at each 
split in the LNA–anti-miR-122 and LNA–anti-miR-122 plus DAA groups. Fresh DAA was also added at each split 
in the DAA and LNA–anti-miR-122 plus DAA groups. During each split, total RNA was extracted for the quan-
tification of HCV RNA and sequence analysis. Transfected LNA–anti-miR-122 continuously showed antiviral 
activity without a reduction in potency until at least 5 days after transfection. Neither the transfection reagent nor 
the LNA-RNA-Control showed any effects on HCV replication (Supplementary Fig. S6).
Cells harboring tat/2A-Neo-H77S were treated with either simeprevir or LNA–anti-miR-122. The concen-
tration of simeprevir was started with 10 nM (5 × EC50). In simeprevir alone cells, the amount of HCV RNA 
gradually decreased until day 12, accompanied by cell death via G418 selection (Fig. 2a,b and Supplementary 
Fig. S7a). However, the amount of HCV RNA subsequently started to increase, which strongly suggested that 
simeprevir-resistant mutants were emerging. In the case of cells treated with 10 nM LNA–anti-miR-122 alone, the 
amount of HCV RNA decreased by day 7 and then reached a plateau, suggesting that LNA–anti-miR-122–resistant 
mutants were unlikely to emerge. In contrast, the amount of HCV RNA continuously decreased in cells treated 
with simeprevir plus LNA–anti-miR-122, and all cells were dead by day 12. Moreover, we obtained the same result 
when we performed a similar experiment in Huh-7.5 cells harboring H77S.3/Blast5A, which has a Blasticidin 
S-coding resistance gene within NS5A (Supplementary Result 2, Supplementary Figs S5b and S7b and S8a,b).
We performed a similar study in Huh-7.5 cells harboring tat/2A-Neo-H77S by treating them with either 
daclatasvir or LNA–anti-miR-122. First, we also started daclatasvir with the concentration of 50 pM (5 × EC50) as 
we did simeprevir, however, all cells died even in a daclatasvir single treatment group (data not shown). Thus, we 
decreased the starting concentration of daclatasvir to 10 pM (1 × EC50). In the cells treated with only daclatasvir, 
the amount of HCV RNA gradually decreased until day 11 (Fig. 2c,d and Supplementary Fig. S7c). However, the 
level began to increase thereafter, strongly suggesting that daclatasvir-resistant mutants were emerging. In cells 
treated with 10 nM LNA–anti-miR-122 alone, the amount of HCV RNA decreased by day 3 and then reached a 
plateau, suggesting that LNA–anti-miR-122–resistant mutants were unlikely to emerge. In contrast, the amount 
of HCV RNA continuously decreased in the cells treated with daclatasvir plus LNA–anti-miR-122, and resulted 
in the death of all cells by day 16.
We performed the same in vitro experiment using sofosbuvir as the simeprevir and daclatasvir experiments. 
First, we started sofosbuvir with the concentration of 250 nM (5 × EC50), however, all cells died even in a sofos-
buvir treatment group (data not shown). Thus, we decreased the starting concentration of sofosbuvir to 50 nM 
(1 × EC50). We treated the cells with sofosbuvir or sofosbuvir plus LNA–anti-miR-122 and gradually increased 
the sofosbuvir concentration. HCV RNA levels sharply decreased in both the sofosbuvir single and combination 
treatment groups until day 11 (Fig. 2e,f and Supplementary Fig. S7d). All cells in the combination treatment 
group died by day 28. We did not observe HCV rebound during our study in the sofosbuvir single treatment 
group, in contrast to the simeprevir and daclatasvir experiments. Interestingly, the cells treated with sofosbuvir 
alone still grew with a low level of HCV RNA, while all cells died in the combination treatment group (Fig. 2f). 
We found that both sofosbuvir alone and combination treatments effectively suppressed HCV replication.
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In summary, these data suggest that combination treatment with a DAA plus LNA–anti-miR-122 can effi-
ciently suppress HCV replication, possibly without the development of DAA-resistant mutants that tend to appear 
after treatment with single DAAs, especially simeprevir and daclatasvir. These data also suggest that treatment 
with 10 nM LNA–anti-miR-122 alone does not completely eliminate HCV from infected cells, although it does 
not seem to lead to the development of resistant mutants.
Sequence Analysis. Based on the above results, we hypothesized that combination treatments might 
suppress HCV replication effectively by preventing the emergence of DAA-resistant mutants. To confirm our 
hypothesis, we performed sequence analysis of HCV RNA in cells treated according to the conditions shown in 
Fig. 2a,c,e. First, we analyzed the HCV RNA from the cells replicating tat/2A-Neo-H77S and treated with either 
simeprevir or LNA–anti-miR-122. Population-based sequence analysis revealed that mutations at NS3 amino 
acid 80 were found in cells treated with simeprevir for 17 days and with simeprevir and LNA–anti-miR-122 for 
12 days. The signal strength suggested that the mutations at amino acid 80 of NS3 were more dominant in the 
Figure 2. In vitro selection experiments in genotype 1a HCV-replicating cells. Huh-7.5 cells harboring 
tat/2A-Neo-H77S were treated with mock, DAA (simeprevir, daclatasvir or sofosbuvir), LNA–anti-miR-122, or 
DAA plus LNA–anti-miR-122 in the presence of G 418. The concentration of DAA was gradually increased, and 
LNA–anti-miR-122 was transfected into Huh-7.5 cells twice a week at cell passage. Schematic representations of 
the experiment using tat/2A-Neo-H77S-replicating cells with simeprevir (a), tat/2A-Neo-H77S-replicating cells 
with daclatasvir (c), and tat/2A-Neo-H77S-replicating cells with sofosbuvir (e). The amount of HCV RNA was 
normalized to that of β -actin mRNA in each group (b,d,f). The arrows in the upper of each figure represent the 
time points of LNA-anti-miR-122 transfection and DAA addition. Results are shown as means + SEM.
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simeprevir single treatment group than in the combination treatment group. Significant simeprevir-resistance 
mutations were not observed in cells from the mock group or the LNA–anti-miR-122 single treatment group on 
day 17 (Fig. 3a).
We performed clonal sequence analysis to examine the HCV sequences in more depth. The F43S mutant was 
the most frequently observed in 52.4% of the clones analyzed on day 12 in the combination treatment group 
(Table 3). This mutant was also the most frequently observed in 75.0% of the clones analyzed at the same time 
point in the simeprevir single treatment group. Interestingly, it was difficult to identify the F43S mutation in the 
combination group via population-based analysis (Fig. 3a). In the mock group, the F43S mutant was much less 
common, and was found in 13.6% of the clones analyzed on day 12. We also observed a low frequency of Q80K 
and D168E mutants in the simeprevir single treatment group, and Q80R, D168E, and F43S + D168E mutants in 
the combination group on day 12. At the last time point, the Q80R, D168E, and N174K mutants were common, 
at 19.0%, 19.0%, and 23.8%, respectively, while F43S, Q80K, D168A, D168V, and I170T mutants were less fre-
quently detected in the simeprevir single treatment group. Some highly drug-resistant mutants, such as D168A 
and D168V, were observed only in the simeprevir single treatment group.
In summary, the Q80R, D168E, and N174K mutants became more central over time in the simeprevir sin-
gle treatment group (Table 3). We also analyzed the HCV RNA from the cells replicating H77S.3/Blast5A that 
were treated with either simeprevir or LNA–anti-miR-122 by population based and clonal sequence analysis. 
Interestingly, the patterns of the mutants and the way the mutants emerged differed from those seen with 
tat/2A-Neo-H77S (Supplementary Results 3, Supplementary Fig. S9 and Supplementary Table S3). However, 
these combination treatments could help to eliminate simeprevir-resistant mutants, which were more common 
in the simeprevir-single treatment in our study.
In a subsequent experiment, we analyzed the HCV RNA from cells replicating tat/2A-Neo-H77S treated with 
either daclatasvir or LNA–anti-miR-122. According to the results of population-based sequence analysis, the 
most frequently observed mutation was at amino acid Q30 in both the daclatasvir single and combination treat-
ment groups. Conversely, there were no significant daclatasvir-resistance mutations in cells from the mock group 
or the LNA–anti-miR-122 single treatment group on day 20 (Fig. 3b).
We next performed clonal sequence analysis. The results showed that the Q30H and Q30R mutants were the 
most frequently observed and that some other mutants, such as M28T, L31M, and L31V, were less frequent in 
the daclatasvir single treatment group on day 11 (Table 4). In the combination treatment group, the Q30H and 
Q30R mutants were also the most frequent, and the M28T and L31M mutants less so on day 11. In the daclatasvir 
single treatment group, the Q30R and Q30H mutants were still the most frequently observed on days 16 and 20, 
while double mutants, such as Q30R + Y93H and Q30R + Y93R, were less frequent. Conversely, the M28T, Q30R, 
Q30H, and L31M mutants observed on day 11 were eliminated by day 16 in the combination treatment group.
We moved on to perform similar sequence analyses in the cells replicating tat/2A-Neo-H77S in the sofosbu-
vir single and combination treatment groups. Because the S282T mutation of NS5B is mainly characterized as a 
sofosbuvir-resistant mutation26,27, we performed population-based sequence analysis by focusing on the regions 
close to S282T. However, the S282T mutation was not observed in either group.
In summary, our study indicated that a DAA combined with LNA–anti-miR-122 has an enhanced resistance 
barrier compared with single DAA treatment.
Discussion
In this study, we focused on a combination of miR-122 antagonism and DAA to overcome the drug resistance 
issues of DAA-based therapies. Previous studies have shown that miR-122 promotes HCV replication by improv-
ing translation, genome stability, and/or RNA amplification15. Therefore, sequestration of endogenous miR-122 
by antisense oligonucleotides could suppress HCV replication. In fact, miR-122 antagonism has been proven to 
suppress HCV replication in HCV-infected cells, as well as chimpanzees and humans12,16,17. Several mutations 
that contribute to anti-miR-122 resistance have been identified in the regions close to two miR-122 binding sites, 
G28A and C3U28. In addition, the insertion of a host U3 snoRNA sequence into stem loop 1 of the HCV 5′ UTR 
impairs the response to miR-122 antagonism18. These mutations were identified in HCV cell culture systems, and 
have not been identified in studies of HCV-infected chimpanzees and humans. Therefore, anti-miR-122 therapy 
is considered to have a much higher barrier to the emergence of drug-resistant variants than DAAs.
We hypothesized that combination treatment with DAA and anti-miR-122 could effectively eliminate HCV 
from infected cells. This hypothesis was partially examined in a previous study by Ottosen et al.22. They showed 
that a combination of miravirsen with interferon-α 2b and several DAAs displayed additive interactions and that 
miravirsen reduced the susceptibility of the DAA-resistant variants. However, the impacts of a combination of 
miravirsen and a DAA on HCV replication and the emergence of DAA-resistant mutants were not examined. 
Accordingly, in the present study, we investigated the usefulness of combination treatments in greater depth.
We found that the combination of LNA–anti-miR-122 and a DAA, such as simeprevir, daclatasvir, or sofos-
buvir, reduced susceptibility to all DAAs in genotype 1a wild-type H77S.3/GLuc2A, although this depended 
on the combinations tested (Supplementary Fig. S4). The best combinations induced more dramatic changes in 
susceptibility to DAAs, as shown in Supplementary Fig. S4. In addition to wild-type HCV, combination treatment 
of DAA-resistant mutants with LNA–anti-miR-122 and DAA alleviated DAA resistance (Table 1; Supplementary 
Table S2 and Table 2), which is consistent with Ottosen’s study22. These results suggest that combination LNA–
anti-miR-122 and DAA treatment should be effective in patients who have pre-existing RAVs.
A synergistic or additive antiviral effect was observed with LNA–anti-miR-122 and DAA treatment of 
DAA-resistant mutants, as well as wild-type virus, therefore we treated HCV-replicating cells with either LNA–
anti-miR-122 or DAA for 2–4 weeks. We used full-length selectable HCV constructs (tat/2A-Neo-H77S and 
H77S.3/Blast5A) containing antibiotic-resistance genes. If the replication of these HCV RNAs was efficiently 
suppressed by either DAA or LNA–anti-miR-122 under antibiotic selection, the cells should die. On the other 
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Figure 3. The results of population-based sequence analysis at the positions reported to be drug resistance 
sites. (a) In the simeprevir experiments, total RNA was extracted at every passage from the tat/2A-Neo-H77S-
replicating cells. We performed analysis targeting the NS3 protease region on day 12 in the combination 
treatment group and on day 17 in the mock, LNA–anti-miR-122, and simeprevir single treatment groups.  
(b) In the daclatasvir experiments, total RNA was extracted from the tat/2A-Neo-replicating cells at every 
passage. We performed analysis targeting the N-terminal region of NS5A on day 16 in the combination 
treatment groups and day 20 in the mocks, LNA–anti-miR-122 and daclatasvir single treatment groups. The 
mutation site is shown within a red rectangular box.
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hand, if DAA-resistant mutants emerged, the cells would not die, despite increasing the DAA concentrations. 
When we treated the cells supporting HCV replication with only simeprevir or daclatasvir, HCV RNA levels 
quickly decreased, but then rebounded later, indicating that simeprevir-/daclatasvir-resistant mutants were estab-
lished. While it was difficult to completely eliminate HCV by single treatment with LNA–anti-miR-122, HCV 
RNA levels were continuously suppressed without rebound during the course of treatment. This result indicates 
that the LNA–anti-miR-122–resistance virus is unlikely to emerge in our model. Importantly, when we treated 
HCV-replicating cells with LNA–anti-miR-122 at EC50 (10 nM) with gradually increasing concentrations of sim-
eprevir or daclatasvir, HCV RNA levels sharply decreased, and all cells were finally killed by antibiotic selection. 
In the case of our experiments with sofosbuvir, all cells treated with LNA–anti-miR-122 plus sofosbuvir died and 
exhibited sharp decreases in HCV RNA levels. In contrast to the experiments with simeprevir and daclatasvir, 
not all cells treated with sofosbuvir died, even after sharp decreases in HCV RNA levels, and HCV continuously 
replicated at a very low level without evidence of rebound.
This phenomenon led us to further study the mechanisms of efficient suppression of HCV using only com-
bination treatment. We hypothesized that the addition of LNA–anti-miR-122 to DAA would prevent the emer-
gence of DAA-resistant mutants. To confirm this hypothesis, we performed two kinds of sequence analyses: 
population-based sequence analysis and clonal sequence analysis. Unexpectedly, we observed DAA-resistant 
variants in both the DAA single and combination treatment groups in the experiments with simeprevir and 
daclatasvir. However, the emergence of DAA-resistant mutants was more efficiently prevented in the combination 
group than the DAA single treatment group. We tested just 10 nM of LNA–anti-miR-122 in the present study. If 
we had used higher concentrations of LNA–anti-miR-122, DAA-resistant mutants could have been prevented 
more effectively. As significant DAA-resistance mutations were not observed in cells from the mock group or the 
LNA–anti-miR-122 single treatment group (Fig. 3a,b), LNA–anti-miR-122 itself does not have any effects on the 
emergence of DAA-resistant mutants. Thus, when LNA–anti-miR-122 was used with DAA, LNA–anti-miR-122 
has the ability to partially prevent the emergence of DAA-resistant mutants which are easily selected or induced 
by a DAA single treatment.
In addition to its specific function in RNA replication, miR-122 could help to mask viral RNA from 
pathogen-recognition receptors, such as RIG-I (DDX58) and IFITs (interferon-induced protein with tetratri-
copeptide repeats)29,30. As these receptors sense RNAs with free 5′ triphosphates and are important antiviral 




anti-miR-122 (day 12) Mock (day 17)
Simeprevir 
(day 17)
F43S 3/22 (13.6%) 15/20 (75.0%) 11/21 (52.4%) 5/23 (21.7%) 2/21 (9.5%)
Q80R 0/22 (0%) 0/20 (0%) 1/21 (4.8%) 0/23 (0%) 4/21 (19.0%)
Q80K 0/22 (0%) 1/20 (5.0%) 0/21 (%) 0/23 (0%) 1/21 (4.8%)
D168E 0/22 (0%) 2/20 (10.0%) 1/21 (4.8%) 0/23 (0%) 4/21 (19.0%)
D168A 0/22 (0%) 0/20 (0%) 0/21 (0%) 0/23 (0%) 1/21 (4.8%)
D168V 0/22 (0%) 0/20 (0%) 0/21 (0%) 0/23 (0%) 1/21 (4.8%)
I170T 0/22 (0%) 0/20 (0%) 0/21 (0%) 0/23 (0%) 1/21 (4.8%)
N174K 0/22 (0%) 0/20 (0%) 0/21 (0%) 0/23 (0%) 5/21 (23.8%)
F43S + D168E 0/22 (0%) 0/20 (0%) 1/21 (4.8%) 0/23 (0%) 0/21 (0%)
WT 19/22 (86.4%) 2/20 (10.0%) 7/21 (33.3%) 18/23 (78.3%) 2/21 (9.5%)
Total 22 20 21 23 21
Table 3.  Frequencies of NS3 Amino Acid Substitutions Determined by Clonal Sequence Analysis in 








(day 16) Mock (day 20)
Daclatasvir 
(day 20)
M28T 2/24 (8.3%) 1/24 (4.2%) 1/24 (4.2%) 0/24 (0%) 1/24 (4.2%)
Q30R 7/24 (29.2%) 5/24 (20.8%) 10/24 (41.7%) 0/24 (0%) 14/24 (58.3%)
Q30H 8/24 (33.3%) 9/24 (37.5%) 10/24 (41.7%) 0/24 (0%) 5/24 (20.8%)
Q30E 0/24 (0%) 0/24 (0%) 0/24 (0%) 0/24 (0%) 1/24 (4.2%)
L31M 1/24 (4.2%) 2/24 (8.3%) 0/24 (0%) 0/24 (0%) 0/24 (0%)
L31V 1/24 (4.2%) 0/24 (0%) 0/24 (0%) 0/24 (0%) 0/24 (0%)
Y93C 0/24 (0%) 0/24 (0%) 0/24 (0%) 0/24 (0%) 1/24 (4.2%)
Q30R + Y93H 0/24 (0%) 0/24 (0%) 1/24 (4.2%) 0/24 (0%) 0/24 (0%)
Q30R + Y93R 0/24 (0%) 0/24 (0%) 0/24 (0%) 0/24 (0%) 1/24 (4.2%)
WT 5/24 (20.8%) 7/24 (29.2%) 2/24 (8.3%) 24/24 (100.0%) 1/24 (4.2%)
Total 24 24 24 24 24
Table 4.  Frequencies of NS5 Amino Acid Substitutions Determined by Clonal Sequence Analysis in 
tat/2A-Neo-H77S-replicating Cells Treated with Mock, Daclatasvir, and Daclatasvir plus LNA–anti-
miR-122.
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factors, miR-122 could diminish innate antiviral defenses against HCV. In most of our experiments, we used 
Huh-7.5 cells, which lack interferon-mediated responses to HCV due to the absence of functional RIG-I and 
TLR3 (Toll-like receptor 3) expression31. Therefore, this sort of additional effect of miR-122 antagonism can be 
excluded. However, in humans, miR-122 antagonism could enhance an endogenous antiviral response, which 
could also help to prevent the development of DAA-resistant mutants.
In the experiments with sofosbuvir, we expected that single treatments would lead to the development of a 
S282T mutation in NS5B because this mutant is known to be quite unfit11, which is consistent with the low level 
of HCV RNA at a later time point. However, this mutation was not found in either the single treatment or com-
bination treatment groups. In depth analyses of an entire NS5B region is required to find new mutations related 
to sofosbuvir resistance.
Clinical trials are required to confirm the safety and efficacy of miR-122 antagonists in humans. However, 
combination treatments with DAA and miR-122 antagonism are strongly expected to become options for patients 
who are unable to eliminate HCV via DAA regimens alone and/or for those who have developed several types of 
RAVs.
Materials and Methods
Reagents. Simeprevir and daclatasvir were purchased from Funakoshi Co., Ltd. (Tokyo, Japan) and sofosbu-
vir was obtained from Cayman Chemical (Ann Arbor, MI). Each was prepared in dimethyl sulfoxide (DMSO), 
the final concentration of which was 0.5%. LNA–anti-miR-122 (miravirsen or SPC3649) was synthesized by 
Nippon Gene Material Co., Ltd. (Toyama, Japan) and diluted in nuclease-free water.
Cells. FT3-7 and Huh-7.5 (Huh-7 derivatives) cells were grown in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum, penicillin, streptomycin, L-glutamine, and non-essential amino acids.
Plasmids. The plasmid pH77S.323 is derived from pH77S32, an infectious molecular clone of genotype 1a 
HCV that contains an additional cell culture-adaptive mutation in E2 and a reversion of Q41R to Q41 in NS3. 
To easily monitor replication, the Gaussia Luciferase (GLuc) coding sequence, fused at its C terminus to the 
foot-and-mouth disease virus (FMDV) 2A autoprotease, was inserted between p7 and NS2 of pH77S.3 and des-
ignated pH77S.3/GLuc2A23. We used plasmids coding several NS3 mutants, which are described in our previous 
study23. NS3 mutations were inserted into pH77S.3/GLuc2A by applying the strategy used in our previous study23. 
The NS5A mutants in the pH77S.3/GLuc2A backbone, such as Q30R and L31V, were kindly provided by David R. 
McGivern and Stanley M. Lemon (The University of North Carolina at Chapel Hill)25.
The full-genomic selectable replicon harboring H77S, tat/2A-Neo-H77S, was modified from the correspond-
ing subgenomic replicon33.
RNA Transcription and Transfection. RNA was synthesized with the T7 RiboMAX™ Express Large 
Scale RNA Production System (Thermo Fisher Scientific Inc., Waltham, MA) after linearization of the plasmids 
with XbaI. Following treatment with RNase-free DNase to remove the template DNA, RNA was purified using 
the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA transfection was carried out using a TransIT mRNA 
Transfection Kit (Takara, Shiga, Japan), according to the manufacturer’s suggested protocol.
LNA–anti-miR-122 Transfection. LNA–anti-miR-122 was transected into Huh-7.5 or FT3-7 cells using 
siPORT NeoFX Transfection Agent (Thermo Fisher Scientific Inc., Rockford, IL) according to the manufacturer’s 
instructions. Transfection mixtures were added to the cell culture plate and overlaid with cell suspensions. Cells 
were then incubated at 37 °C under 5% CO2. Three separate transfections were performed, and each was analyzed 
in triplicate.
In Vitro Selection Experiments. HCV RNA (tat2A-Neo-H77S) was transfected into Huh-7.5 cells by 
electroporation as previously describeb14. Cells were then seeded in 10-cm dishes containing Dulbecco’s mod-
ified Eagle’s medium supplemented with 1 mg/mL G418. HCV-replicating cells were seeded in 10-cm dishes 
and transfected with LNA–anti-miR-122 at 10 nM using siPORT NeoFX Transfection Agent. DAAs (sime-
previr, daclatasvir, or sofosbuvir) were added to the cells at EC50 values and their concentrations were gradually 
increased. LNA–anti-miR-122 was transfected into cells during twice-weekly passage, at which time total RNA 
was also extracted.
Luciferase Activity Assay. Following RNA transfection, cell culture supernatant fluids were collected and 
fresh medium was added at 24-hour intervals. Secreted GLuc activity was measured in 50-μ L aliquots of the 
supernatant using the GLuc Assay Kit (New England Biolabs, Ipswich, MA) according to the manufacturer’s sug-
gested protocol. Luminescent signals were measured on a GloMax® -Multi + Microplate Multimode Reader with 
Instinct® (Promega, Fitchburg, WI).
Antiviral Activity Assays. Wild-type and mutant viral RNAs were transfected as described above. Medium 
containing serial dilutions of the antiviral compounds was freshly replaced at 24-hour intervals thereafter. 
Secreted GLuc activity was determined 72 hours post-transfection, as described above. The concentration of each 
compound required to reduce the amount of secreted GLuc activity by 50% (antiviral EC50) was determined 
using a three-parameter Hill equation (SigmaPlot 12.5, Systat Software, Inc. Chicago, IL). The synergy of the 
DAAs (simeprevir, daclatasvir, and sofosbuvir) plus LNA–anti-miR-122 for virus treatment was evaluated by the 
method of Chou and Talalay with CalcuSyn Software (CalcuSyn, The ComboSyn Inc. Paramus, NJ)24.
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qRT-PCR for HCV RNA. Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany), and 
cDNA was synthesized with a high-capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA). 
The primer pairs and probes for HCV and β -actin were obtained from the TaqMan assay reagents library. HCV 
RNA was detected as described previously34.
Sequence Analysis of HCV RNAs. Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) 
according to the instructions, and cDNA was synthesized with a high-capacity cDNA reverse transcription kit 
(Applied Biosystems) using random primers. For population-based sequence analysis of the NS3 protease (amino 
acids 1–180) and the N-terminal region of NS5A (amino acids 1–100), cDNA was amplified using the follow-
ing set of primers: for NS3, NS3F1BamHI: 5′ -TTAGGATCCGCGGCGTGTGG GGACATCAT-3′ containing an 
artificial BamHI site at its 5′ end and NS3R1XbaI: 5′ -TTATCTAGAT TGCCGCTGCC AGTGGGAGC-3′ con-
taining an artificial XbaI site at its 5′ end; for NS5A, NS5AF1: 5′ -TCACTGCCAT ACTCAGCAG-3′ and NS5AR1: 
5′ -CAGTAGTCAT ACCCGATACG-3′ . The DNA sequences of the PCR products were determined by the con-
ventional Sanger method. In clonal sequence analysis, amplicons spanning the NS3 protease region were digested 
by BamHI and XbaI and then inserted into pGEM® -3Zf(+ ) vector (Promega), which was also digested with 
BamHI and XbaI. The amplicons spanning NS5A were directly inserted into pGEM® -T Easy Vector (Promega). 
We transformed DH5α Competent Cells (Takara) with the ligation products and then extracted plasmid DNA 
from the transformed DH5α cells. The DNA sequence of plasmid DNA was determined by the conventional 
Sanger method.
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